



Reference number
4459-A

Aetna Medicare Part B Drug Criteria

CEREZYME (imiglucerase)

This policy is for Aetna Medicare members. [Find the Aetna Commercial Medical Drug Criteria.](#)

For Aetna Medicare members, National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) will be applied to Part B drug requests when applicable. Aetna Medicare Part B Drug Criteria documents will be used in the absence of an NCD and LCD.

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications

Cerezyme is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions: anemia, thrombocytopenia, bone disease, and/or hepatomegaly or splenomegaly.

B. Compendial Uses

1. Gaucher disease type 2
2. Gaucher disease type 3

All other indications will be assessed on an individual basis. Submissions for indications other than those enumerated in this policy should be accompanied by supporting evidence from Medicare approved compendia.

II. DOCUMENTATION

The following documentation must be available, upon request, for all submissions:

For initial requests: beta-glucocerebrosidase enzyme assay or genetic testing results supporting diagnosis.

III. CRITERIA FOR INITIAL APPROVAL

A. **Gaucher disease type 1**

Authorization of 12 months may be granted for treatment of Gaucher disease type 1 when the diagnosis of Gaucher disease was confirmed by enzyme assay demonstrating a deficiency of beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.

B. Gaucher disease type 2

Authorization of 12 months may be granted for treatment of Gaucher disease type 2 when the diagnosis of Gaucher disease was confirmed by enzyme assay demonstrating a deficiency of beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.

C. Gaucher disease type 3

Authorization of 12 months may be granted for treatment of Gaucher disease type 3 when the diagnosis of Gaucher disease was confirmed by enzyme assay demonstrating a deficiency of beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.

IV. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must be currently receiving therapy with the requested agent.

Authorization for 12 months may be granted when all of the following criteria are met:

- A. The member is currently receiving therapy with the requested medication.
- B. The requested medication is being used to treat an indication enumerated in Section III.
- C. The member is receiving benefit from therapy. Benefit is defined as not experiencing an inadequate response or any intolerable adverse events from therapy.

V. SUMMARY OF EVIDENCE

The contents of this policy were created after examining the following resources:

- 1. The prescribing information for Cerezyme.
- 2. The available compendium
 - a. National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium
 - b. Micromedex DrugDex
 - c. American Hospital Formulary Service- Drug Information (AHFS-DI)
 - d. Lexi-Drugs
 - e. Clinical Pharmacology
- 3. Gaucher disease: GeneReviews
- 4. Revised recommendations for the management of Gaucher disease in children
- 5. Management of neuronopathic Gaucher disease: revised recommendations. European Working Group on Gaucher Disease

After reviewing the information in the above resources, the FDA-approved indications listed in the prescribing information for Cerezyme are covered in addition to the following:

- A. Gaucher disease type 2
- B. Gaucher disease type 3

VI. EXPLANATION OF RATIONALE

Support for FDA-approved indications can be found in the manufacturer’s prescribing information.

The diagnosis of Gaucher disease is made when deficient glucocerebrosidase (glucosylceramidase) enzyme activity in peripheral blood leukocytes or other nucleated cells or by the identification of biallelic pathogenic variants in *GBA* gene (Pastores and Hughes).

Support for using Cerezyme to treat Gaucher disease type 2 can be found in the National Organization for Rare Disorders Guide to Rare Disorders. Enzyme replacement therapy (ERT) is effective for type 1 disease. Anemia and thrombocytopenia improve, hepatomegaly and splenomegaly are reduced, and skeletal damage is ameliorated with ERT. These systemic manifestations also improve with ERT in patients with type 2 and 3 disease. However, it should be noted that ERT does not reverse brain damage in patients with type 2 disease.

Support for using Cerezyme to treat Gaucher disease type 3 can be found in the Revised Recommendations for the Management of Gaucher Disease by Kaplan et al. The guideline indicates symptomatic children with types 1 or 3 disease should receive enzyme replacement therapy, which will prevent debilitating and often irreversible disease progression and allow those with non-neuropathic disease to lead normal healthy lives.

VII. REFERENCES

1. Cerezyme [package insert]. Cambridge, MA: Genzyme Corporation; December 2021.
2. Altarescu G, Hill S, Wiggs E, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. *J Pediatr.* 2001;138:539-547.
3. Erikson A, Forsberg H, Nilsson M, Astrom M, Mansson JE. Ten years’ experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease. *Acta Paediatr.* 2006;95:312-317.
4. Pastores GM, Hughes DA. Gaucher Disease. 2000 July 27 [Updated June 21, 2018]. In: Adam MP, Everman DB, Mirzaa GM, et al, editors. GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2022.
5. Kaplan P, Baris H, De Meirleir L, et al. Revised recommendations for the management of Gaucher disease in children. *Eur J Pediatr.* 2013;172:447-458.
6. National Organization for Rare Disorders. (2003). *NORD guide to rare disorders*. Philadelphia: Lippincott Williams & Wilkins.

Revised: November 2023

Aetna Medicare Utilization Management Committee Approved: November 2023

See Evidence of Coverage for a complete description of plan benefits, exclusions, limitations and conditions of coverage. Plan features and availability may vary by service area.